Previous 10 | Next 10 |
Mitsubishi Tanabe Pharma America ( OTCPK:MTZPY -1.5% ) initiates a Phase 3 clinical trial, BouNDless , evaluating continuous subcutaneously administered carbidopa/levodopa (ND0612) compared to the oral formulation in Parkinson's disease (PD) patients. More news on: Mitsubishi Tanabe P...
Genmab A/S (NASDAQ: GMAB ) initiated with Overweight rating and $30 (58% upside) price target at Morgan Stanley. Initiated with Outperform rating and $23 price target at RBC. Shares up 1% premarket. More news on: Genmab A/S, Fulcrum Therapeutics, Inc., Mirum Pharmaceuticals, In...
Axovant Gene Therapies (NASDAQ: AXGT ): Q1 GAAP EPS of -$1.23 misses by $0.30 . More news on: Axovant Gene Therapies Ltd., Earnings news and commentary, , Read more ...
SUNRISE-PD Phase 2 trial of AXO-LENTI-PD for Parkinson's disease continues to enroll patients in second dose cohort with data expected in the fourth quarter of calendar 2019 Data from patients dosed with AXO-AAV-GM1 and AXO-AAV-GM2 expected in fourth quarter of calendar 2019 Net loss...
Neurocrine Biosciences ( NBIX ) was never set up for a great year in 2019 from a clinical data/pipeline perspective, but management is compensating so far with strong sales execution with its approved drug Ingrezza. With the company now free cash flow positive, management has a lot of option...
Unlike many prior proposals that would have minimal impact in controlling the cost of pharmaceuticals, two recently proposed legislative actions could meaningfully reduce Medicare drug spending. One is aimed at Medicare Part D , which represented $100 billion of the $130 billion spent by ...
-Details from ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD and AXO-AAV-GM2 program highlighted in poster presentations- BASEL, Switzerland, June 24, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, anno...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) rose last week, rising from 3,270.31 points on Monday’s (June 17) open to settle at 3,429.16 points as of 3:20 p.m. EDT on Friday (June 21). On Wednesday (June 19), Melinta Therapeutics (NASDAQ: MLNT ) revealed that the US Food and D...
Gainers: Axovant Gene Therapies (NASDAQ: AXGT ) +40% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +24% . India Globalization Capital (NYSEMKT: IGC ) +17% . Pintec Technology (NASDAQ: PT ) +14% . ObsEva SA (NASDAQ: OBSV ) +12% . Overstock.com (NASDAQ: OSTK ) +12% . Fuwei Films (NASDAQ...
It is a great time to be investing in healthcare stocks. Sentiment is not overly positive and Medicare For All remains an overhang (it will not be implemented within the next ten years), yet I maintain that the outlook for continued growth, driven by the prevalence of chronic disease and demog...
News, Short Squeeze, Breakout and More Instantly...
Axovant Gene Therapies Ltd. Company Name:
AXGT Stock Symbol:
NYSE Market:
On-track to report t opline r esults from low-dose cohort by end of 2020 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to ra...
A pioneering researcher , Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapy Dr. Gao recently served as President of the American Society for Gene and Cell Therapy (ASGCT) and has been ranked as one of...
Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicines Company’s common stock will trade on the NASDAQ under new ticker “SIOX” effective November 13, 2020 ...